Cargando…

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats

BACKGROUND/AIMS: The search for new therapies providing cardiorenal protection in chronic kidney disease (CKD) has led to treatments that combine conventional renin-angiotensin-aldosterone-system inhibitors with other drugs that exhibit potential in disease management. METHODS: In rats made uremic b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ritter, Cynthia, Zhang, Sarah, Finch, Jane L., Liapis, Helen, Suarez, Edu, Ferder, Leon, Delmez, James, Slatopolsky, Eduardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225010/ https://www.ncbi.nlm.nih.gov/pubmed/25300759 http://dx.doi.org/10.1159/000355811

Ejemplares similares

Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid and aorta of uremic rats
por: Ritter, Cynthia S., et al.
Publicado: (2015)

Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
por: Sagar, Priyanka S., et al.
Publicado: (2021)

Effects of enalapril and paricalcitol treatment on diabetic nephropathy and renal expressions of TNF-α, p53, caspase-3 and Bcl-2 in STZ-induced diabetic rats
por: Ahmed, Osama M., et al.
Publicado: (2019)

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2019)

High-Dose Enalapril Treatment Reverses Myocardial Fibrosis in Experimental Uremic Cardiomyopathy
por: Tyralla, Karin, et al.
Publicado: (2011)

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma
por: Groenewegen, G, et al.
Publicado: (2012)

Endothelin A Receptor Antagonist, Atrasentan, Attenuates Renal and Cardiac Dysfunction in Dahl Salt-Hypertensive Rats in a Blood Pressure Independent Manner
por: Samad, Mohammed A., et al.
Publicado: (2015)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight
por: Koomen, Jeroen V., et al.
Publicado: (2018)

Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy
por: Kang, Wen-Ling, et al.
Publicado: (2016)

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients
por: Pihlstrøm, Hege Kampen, et al.
Publicado: (2020)

Corrigendum: Atrasentan increased the expression of klotho by mediating miR-199b-5p and prevented renal tubular injury in diabetic nephropathy
por: Kang, Wen-Ling, et al.
Publicado: (2018)

The Effect of Enalapril, Losartan, or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients
por: Andrade-Sierra, Jorge, et al.
Publicado: (2022)

Is the combination of enalapril and losartan irrational?
por: Parmar, D.M., et al.
Publicado: (2008)

The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder
por: Slatopolsky, Eduardo
Publicado: (2011)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
por: Oliva-Damaso, Elena, et al.
Publicado: (2016)

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease
por: Keber, Tajda, et al.
Publicado: (2017)

Anti-inflammatory and anti-apoptotic effects of paricalcitol in lipopolysaccharide-induced renal proximal tubular cell injury
por: Kim, Soo Wan
Publicado: (2017)

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Webb, David J., et al.
Publicado: (2017)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure
por: Ma, Xiao-Ying, et al.
Publicado: (2023)

Hemodynamic and mitochondrial effects of enalapril in experimental sepsis
por: Pereira, AJ, et al.
Publicado: (2013)

Efficacy of Topical Enalapril in Treatment of Hypertrophic Scars
por: Mohammadi, Ali Akbar, et al.
Publicado: (2018)

Amlodipine/enalapril: Lack of efficacy: case report
Publicado: (2022)

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease
por: Smeijer, J. David, et al.
Publicado: (2022)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

50 Years of Research and Discovery in Chronic Kidney Disease and Mineral & Bone Disorder: The Central Role of Phosphate
por: Slatopolsky, Eduardo, et al.
Publicado: (2011)

The effect of renal diet in association with enalapril or benazepril on proteinuria in dogs with proteinuric chronic kidney disease
por: Zatelli, A., et al.
Publicado: (2016)

Covid-19 and adolescent acute kidney injury: Renal recovery with combined enalapril and estrogen therapy
por: Sills, E. Scott, et al.
Publicado: (2022)

Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis
por: Wu-Wong, J. Ruth, et al.
Publicado: (2010)

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis
por: Liu, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4c93cki198165cjfs9fmdc2md3